Possible 'Best-in-Class' Alzheimer's Drug Candidate Offers 'Disruptive' Potential

Disclosures from Mackie Research, ProMis Neurosciences Inc., Initiating Coverage, Sept. 19, 2017

ANALYST CERTIFICATION: I, Andre Uddin, certify the views expressed in this report were formed by my review of relevant company data and industry investigation, and accurately reflect my opinion about the investment merits of the securities mentioned in the report. I also certify that my compensation is not related to specific recommendations or views expressed in this report.

RELEVANT DISCLOSURES APPLICABLE TO COMPANIES UNDER COVERAGE: Relevant disclosures required under IIROC Rule 3400 applicable to companies under coverage discussed in this research report are available on our web site at www.mackieresearch.com.